Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Apr 6;56(4):405-421. doi: 10.3760/cma.j.cn112150-20211130-01106.
Atherosclerotic cardiovascular disease is the general name of a series of diseases based on atherosclerosis. With the development of the social economy and the progress of population aging in China, the burden of atherosclerotic cardiovascular disease is increasing. However, in recent years some clinical studies have proved that the traditional blood lipid indicators, including low-density lipoprotein cholesterol, have some limitations in the risk control of atherosclerotic cardiovascular disease, and the blood lipid indicators need to be further supplemented and improved. This consensus expounds non-traditional blood lipid indexes from the perspectives of test and clinic, mainly including apolipoprotein B and lipoprotein a, non-high density lipoprotein cholesterol and lipoprotein residue, and non-fasting blood lipid. This consensus systematically expounds the pathophysiological mechanism of non-traditional blood lipid indexes, the relationship with cardiovascular disease, detection methods and performance, intervention, control and application in the state of cardiovascular disease, and gives the corresponding clinical expert suggestion.
动脉粥样硬化性心血管疾病是一系列基于动脉粥样硬化的疾病的统称。随着我国社会经济的发展和人口老龄化进程的推进，动脉粥样硬化性心血管疾病的负担日益加重。然而，近年来一些临床研究证明，包括低密度脂蛋白胆固醇在内的传统血脂指标在动脉粥样硬化性心血管疾病的风险控制方面存在一定局限性，血脂指标有待进一步补充和完善。本共识从检测和临床角度阐述了非传统血脂指标，主要包括载脂蛋白B和脂蛋白a、非高密度脂蛋白胆固醇和脂蛋白残粒，以及非空腹血脂。本共识系统阐述了非传统血脂指标的病理生理机制、与心血管疾病的关系、检测方法及性能、干预措施、在心血管疾病状态下的控制与应用，并给出了相应的临床专家建议。
